Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,625,675
  • Shares Outstanding, K 101,091
  • Annual Sales, $ 351,320 K
  • Annual Income, $ -7,230 K
  • 60-Month Beta 1.59
  • Price/Sales 31.87
  • Price/Cash Flow N/A
  • Price/Book 41.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.06
  • Number of Estimates 5
  • High Estimate 0.14
  • Low Estimate 0.01
  • Prior Year 0.02
  • Growth Rate Est. (year over year) +200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.03 +38.25%
on 09/08/20
110.98 -5.29%
on 09/18/20
+26.51 (+33.73%)
since 08/21/20
3-Month
55.40 +89.73%
on 07/14/20
110.98 -5.29%
on 09/18/20
+41.74 (+65.87%)
since 06/19/20
52-Week
53.40 +96.84%
on 03/23/20
110.98 -5.29%
on 09/18/20
+23.74 (+29.18%)
since 09/20/19

Most Recent Stories

More News
US FDA Starting to Grant Fast-Track Designation for Glioblastoma Treatments

Unfortunately, glioblastoma is an aggressive brain tumor that still remains difficult to treat. To ...

KZIA : 6.69 (-1.62%)
PSTV : 2.75 (-6.46%)
NVCR : 105.11 (-5.08%)
AZN : 55.91 (-0.96%)
WBIO.CN : 0.280 (+1.82%)
Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that William Doyle, the company's Executive Chairman, and Dr. Uri Weinberg, the company's Chief Science Officer, will participate in the 2020 Wells Fargo Virtual...

NVCR : 105.11 (-5.08%)
Novocure Announces Expansion of Its Executive Leadership Team

--Ashley Cordova promoted to Chief Financial Officer

NVCR : 105.11 (-5.08%)
Sophisticated Medical Devices Allow for Improved Patient Monitoring

, /PRNewswire/ -- Medical devices range from simple tongue depressors and bedpans to complex programmable pacemakers and closed loop artificial pancreas systems. In addition, in vitro diagnostic (IVD)...

NMRD : 3.65 (-2.67%)
NVCR : 105.11 (-5.08%)
RMD : 171.51 (+0.88%)
BSX : 38.55 (+0.18%)
IRTC : 225.33 (-3.43%)
Novocure Announces Launch of MyLink(TM) to Enable Patient-Guided, Remote Download of Optune(R) Usage Data

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure...

NVCR : 105.11 (-5.08%)
China NMPA Approves Optune(R) for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

--A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate(1)

NVCR : 105.11 (-5.08%)
ZLAB : 73.30 (-7.53%)
China NMPA Approves Optune(R) for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years

NVCR : 105.11 (-5.08%)
ZLAB : 73.30 (-7.53%)
NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 105.11 (-5.08%)
Novocure Reports First Quarter 2020 Financial Results and Provides Company Update

--Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities

NVCR : 105.11 (-5.08%)
NVE Schedules Conference Call on Fourth-Quarter and Fiscal Year Results

NVE Corporation (Nasdaq:NVEC) announced that it plans to release its financial results for the quarter and fiscal year ended March 31, 2020 on Wednesday, May 6, 2020 after the close of the Nasdaq Regular...

NVCR : 105.11 (-5.08%)
NVEC : 50.11 (-4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 111.96
1st Resistance Point 108.53
Last Price 105.11
1st Support Level 102.10
2nd Support Level 99.10

See More

52-Week High 110.98
Last Price 105.11
Fibonacci 61.8% 88.98
Fibonacci 50% 82.19
Fibonacci 38.2% 75.40
52-Week Low 53.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar